Shanghai Huaota Biopharmaceutical Co., Ltd. announced on July 29 that China's National Medical Products Administration (NMPA) has approved HB0034, an anti-interleukin-36 receptor (IL-36R) monoclonal antibody, for the treatment of flares in adult patients with generalized pustular psoriasis (GPP). According to the company, the decision makes HB0034 the first domestically developed IL-36R antibody to reach the Chinese market.
GPP is a rare, life-threatening neutrophilic skin disease characterized by widespread erythema and sterile pustules, frequently accompanied by systemic symptoms such as fever, arthralgia, elevated C-reactive protein and leukocytosis. Acute flares have been associated with sepsis and multi-organ failure. The condition was added to China's second batch of rare disease catalog in 2023.
HB0034 was originally developed by Huabo Biopharm (Shanghai) Co., Ltd., a subsidiary of Shanghai Huaota Biopharmaceutical Co., Ltd. The antibody is designed to block the IL-36 receptor pathway and reduce downstream inflammatory signaling. Approval rests on a pivotal Phase 2 study in which a single intravenous dose of HB0034 was compared with placebo in patients experiencing a GPP flare. The trial met its primary endpoint in March 2025, with patients in the HB0034 arm showing notable clearance of skin pustules at week 1, according to the company. The company also reported a favorable safety profile, with no new safety signals identified.
The only other IL-36R antibody currently approved anywhere in the world is Boehringer Ingelheim's spesolimab, which is also marketed in China. With HB0034, Huaotai becomes the second company globally to bring an anti-IL-36R antibody to market, and the first in China with a domestically originated molecule.
The original Chinese-language announcement did not disclose pricing, launch timing, additional indications under development, or the clinical trial registration number for the Phase 2 study.